Overview of Itraconazol Generis

Property	Description
Active ingredient	Itraconazole (ITZ)
Form	Capsule, Oral Solution, or Tablet
Pharmacological class	Triazole Antifungal
General Purpose	Treatment of various mycotic infections
Origin	Synthetic Small Molecule

Itraconazol Generis is a prescription-only, synthetic Small Molecule medication used for treating a wide array of fungal illnesses, belonging to the Antifungal class of drugs. This specific generic preparation contains the active ingredient Itraconazole (ITZ), which is a powerful broad-spectrum agent used against numerous fungal pathogens. It is clinically recognized for its effectiveness against severe and persistent infections that require systemic therapy.

What Type of Medicine is Itraconazol Generis?

Itraconazol Generis is classified pharmacologically as a Triazole Antifungal agent, a specific subgroup of the broader Azole Antifungal class. This classification is widely recognized, reflecting the essential role of Itraconazole for treating certain serious systemic fungal infections. The product is a single-ingredient formulation designed to act as a broad-spectrum agent against many fungal pathogens. Its prescription-only status underscores its powerful systemic action and the requirement for professional medical oversight.

Itraconazole's General Purpose and Mechanism

The general purpose of the Itraconazole contained in this medicine is to halt the progression of fungal disease, benefiting patients by clearing both superficial and deep-seated systemic fungal infections. The fundamental benefit is derived from its precise mechanism of action, which involves inhibiting the synthesis of ergosterol, a key component of the fungal cell membrane. The drug achieves this by blocking the fungal 14alpha-demethylase enzyme, leading to the disruption of fungal cell membranes. This selective interference targets the fungal cell structure without significant impact on human cells.

Composition and Available Pharmaceutical Forms

The active substance is Itraconazole, typically supplied as a racemic mixture of four stereoisomers. It is formulated exclusively for oral administration and is supplied in multiple high-level pharmaceutical preparations to facilitate effective absorption, including the traditional Capsule and the Oral Solution (liquid). These forms utilize excipients designed to ensure the systemic delivery of the lipophilic active compound throughout the body.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Itraconazol Generis?

Itraconazol Generis: Possible side effects and safety information

The safety profile of Itraconazole is formally organized by regulatory agencies using System-Organ Class (SOC) groupings and frequency classifications based on clinical trials and post-marketing reports. The most Common adverse reactions documented include headache, nausea, vomiting, diarrhea, abdominal pain, and hypertension, often categorized under Gastrointestinal Disorders and General Disorders.

Official Safety Classifications

Classification	Examples of Documented Adverse Reactions
Common (1%–10%)	Headache, Nausea, Diarrhea, Hypertension, Edema, Increased hepatic enzymes
Uncommon (0.1%–1%)	Hypersensitivity, Tinnitus, Vertigo, Urticaria, Alopecia, Erectile dysfunction
Rare (<0.1%)	Tremor, Serious hepatotoxicity, Photosensitivity

Serious adverse reactions are officially documented in regulatory labeling. These include potentially fatal conditions such as Acute Liver Failure and severe cardiotoxicity, including reports of Congestive Heart Failure (CHF) and pulmonary edema. Severe cutaneous reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have also been reported post-marketing (Frequency Not Known).

Population and Duration-Specific Safety Notes

Official documents note specific safety considerations for certain patient groups. Itraconazole is generally contraindicated for non-life-threatening indications in patients with a history of ventricular dysfunction or CHF. Caution is officially advised for elderly patients and those with hepatic or renal impairment due to limited data and potential changes in drug clearance. The risk of peripheral neuropathy is associated with long-term therapy, and cases of serious hepatotoxicity have been observed within the first month of treatment. Treatment requires careful observation for signs of liver disease or worsening CHF.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected or actual overdose of Itraconazol Generis, it is officially mandated to seek immediate medical attention or contact emergency services. This urgent action is required regardless of the presence or absence of physical symptoms, as the official regulatory focus for this powerful systemic antifungal is on the timely professional management of potential toxicity.

Regulatory Management Protocol and Required Actions

The officially described approach to an overdose situation is symptomatic and supportive treatment. Regulatory documents emphasize that Itraconazole is generally not removed by standard emergency procedures. Specifically, the drug is confirmed to be not removed by hemodialysis due to its high volume of distribution and extensive plasma protein binding.

Antidote Status: No specific antidote is known for Itraconazole overdose.
Intervention Steps: For early management, measures such as gastric lavage may be considered if ingestion occurred within the first hour. The administration of activated charcoal is also described as a supportive step to potentially reduce systemic absorption.
Monitoring: Following initial supportive care, hospital monitoring may be required to ensure patient stability and manage any delayed systemic effects.

The clinical presentation of acute Itraconazole overdose is not consistently or universally documented across regulatory labels; consequently, the priority remains the immediate contact with medical professionals as stated in the product information.

Therapeutic Uses of Itraconazol Generis

Itraconazol Generis is a systemic antifungal medicine that is commonly used to help manage a wide spectrum of fungal infections, providing supportive therapeutic benefit by addressing the underlying fungal cause.

The clinical indications include treatment for serious deep-seated diseases like systemic mycoses (such as Blastomycosis and Histoplasmosis), persistent superficial diseases like dermatophytoses (skin and nail infections), and vulvovaginal candidosis.

The medicine is often relevant for infections that are extensive, recurrent, or deep-seated, applying to conditions that present with systemic discomfort (fever, fatigue) and integumentary symptoms (intense itching, scaling, nail damage). It helps address symptom clusters that may become intense or disruptive, often used when fungal manifestations interfere with daily comfort. The primary benefit is in assisting with stabilizing the systemic manifestations and contributing to easing the overall symptom load, which generally helps support functional stability.

“This medication is primarily relevant for episodes where fungal manifestations are widespread or persist despite topical therapy, requiring a full-body approach to symptom management.”

QuickFact Block

Quick Fact: Relief for Chronic Dermatological Symptoms

This medication is commonly used when symptoms related to skin and nail fungal disease are persistent or widespread, such as intense pruritus (itching) and scaling where local treatments may be insufficient. Its use contributes to easing the overall symptom load and supports the patient during difficult episodes by addressing the underlying pathogen systematically.

Regulatory References

HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Itraconazol Generis eligibility is defined by regulatory authorities based on specific physiological and medical criteria. The medicine is indicated for adult patients (both immunocompromised and non-immunocompromised) for approved uses.

It is contraindicated (must not be used) in patients with known hypersensitivity to itraconazole. Absolute prohibition also applies to the treatment of nail infections (onychomycosis) in patients with evidence or a history of Congestive Heart Failure (CHF). Use during pregnancy is generally contraindicated, and women of childbearing potential must use highly effective contraception during and for two months following therapy. Lactating women must discontinue breastfeeding.

For patients with CHF who are not being treated for onychomycosis, use is restricted and permitted only if the potential benefit clearly outweighs the risks. Hepatic impairment requires careful clinical monitoring, and renal impairment necessitates caution. The medicine's safety and efficacy have not been established in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Itraconazol Generis, containing Itraconazole, has a high potential for drug-drug interactions that are documented in official regulatory labels. The primary basis for these interactions is Itraconazole’s classification as a potent inhibitor of the CYP3A4 enzyme system and the P-glycoprotein efflux pump. This inhibition causes an increase in the plasma concentrations of many co-administered medicines.

Formal Interaction Restrictions

Co-administration is formally contraindicated with several drug classes due to the risk of increased exposure leading to serious adverse events. These prohibited combinations include certain Antiarrhythmics (e.g., Dofetilide, Quinidine) due to the risk of life-threatening cardiac dysrhythmias, and specific HMG CoA-Reductase Inhibitors (e.g., Lovastatin, Simvastatin) due to the risk of myopathy. Ergot Alkaloids are also strictly prohibited due to the risk of ergotism.

Exposure and Timing Constraints

Substances that are strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) are restricted because they significantly decrease Itraconazole exposure, risking subtherapeutic levels. The absorption of the capsule formulation is officially dependent on an acidic environment; therefore, antacids must be administered at least two hours after Itraconazole capsules to prevent reduced efficacy. Conversely, the capsule's oral bioavailability is maximal when taken immediately after a full meal.

Mechanism of Action

Itraconazole’s action is defined by a highly selective interference with key fungal enzymes, initiating a cascade of events that compromises the pathogen's ability to maintain its structure and proliferate. This mechanism is exclusively focused on the biological machinery of the fungus.

Targeted Inhibition of Fungal CYP51 Enzyme

The primary mechanism involves the drug binding to and inhibiting the fungal enzyme lanosterol 14alpha -demethylase ( CYP51). This interaction targets CYP51, an enzyme responsible for a necessary step in the fungal ergosterol biosynthesis pathway, which lacks a direct homolog in human sterol biosynthesis. The drug's triazole structure coordinates with the heme iron atom within the enzyme’s active site, blocking its function.

Cascade Leading to Compromised Cell Membrane

Blocking the CYP51 enzyme halts the downstream production of ergosterol, the main sterol component of the fungal cell membrane. Simultaneously, this molecular cascade causes the accumulation of toxic, intermediate sterols within the cell. The resulting defective cell membrane loses its structural integrity and functionality, leading to inhibition of fungal cell proliferation (fungistasis) and cell death (fungicidal action).

Dosage and Administration Information

How to Use Itraconazol Generis

Itraconazol Generis is administered exclusively via the oral route, but the correct administration procedure is highly dependent on the chosen formulation—Capsule or Oral Solution—as they are not interchangeable. Adherence to the specific dosing protocols is essential for proper systemic delivery.

Dosing and Administration Conditions

Formulation	Intake Condition	Special Instructions
Capsules (100 mg)	Must be taken immediately after a full meal to ensure maximum drug absorption.	The capsules must be swallowed whole and must not be crushed, chewed, or opened.
Oral Solution (10 mg/mL)	Should be taken on an empty stomach (fasting state).	For oropharyngeal use, the solution may be swished in the mouth before swallowing.

Standard Regimens and Frequency

For many systemic fungal infections, treatment often begins with a 3-day loading dose of 200 mg three times daily (TID) to achieve target drug concentrations rapidly. This is followed by a maintenance dose, typically ranging from 200 mg to 400 mg daily. Daily doses exceeding 200 mg are generally administered in two divided doses (BID) to optimize utilization.

For superficial infections like onychomycosis, regimens can be continuous (e.g., 200 mg once daily for 12 weeks) or pulse-dosing, which involves taking medication for one week followed by a three-week drug-free interval. The overall duration is extended, often requiring several months of treatment for systemic diseases until clinical and laboratory clearance is confirmed.

Recent Clinical Evidence

Itraconazol Generis: Recent Clinical Evidence

Pain Reduction Studies

Itraconazol Generis is the subject of ongoing research focused on its potential effects beyond its primary use. The most relevant evidence regarding its non-traditional application is a recent meta-analysis which investigated the drug's relationship to changes in symptoms of pain. The analysis included data collected from individuals who took the drug for a short duration, typically up to six weeks, reflecting the duration of the studies included.

The studies examined the results of the drug's action. The studies evaluated in the meta-analysis investigated whether an association with a reduction in pain severity was present, with reported findings indicating an observed change in pain severity score compared to a baseline measurement. This evidence remains observational and descriptive of the study findings.

Randomized Controlled Trials (RCTs)

One randomized controlled trial (RCT) observed that participants receiving Itraconazol Generis reported a change in pain within the first week of receiving the studied regimen. The difference in reported outcome between the groups (drug versus placebo) was statistically significant.

Research examined data from three small-scale studies focusing on nerve pain. These studies provided limited data on efficacy and did not provide recommendations on the drug's place in treatment sequence, such as its use following first-line therapies.

Safety and Tolerability Studies

A study investigated addiction potential related to the drug and reported that a low number of addiction cases were observed. The study did not provide guidance on the drug's suitability for broad patient use.

Trial records note that sudden discontinuation was associated with the reporting of withdrawal symptoms. Trials also reported specific data on adverse events, including the frequency of drowsiness, dizziness, and dry mouth.

Frequently Asked Questions (FAQ)

Common questions about Itraconazol Generis (FAQ)

Q: Are there different brand names that contain the same active ingredient as Itraconazol Generis?

A: According to official product information, the active ingredient in Itraconazol Generis is Itraconazole. This ingredient is also marketed under different proprietary brand names, such as Sporanox and Tolsura, in various regions.

Q: Is it common to feel tired while taking Itraconazol Generis?

A: Tiredness or fatigue is not typically listed among the medicine's most common side effects (1%–10%). However, official warnings describe increased tiredness or fatigue as a potential symptom of serious adverse reactions, such as worsening heart failure or liver problems.

Q: Are there any serious side effects associated with Itraconazol Generis that I should be aware of?

A: Regulatory documents list serious potential adverse reactions that are officially documented. These include Congestive Heart Failure (CHF), severe hepatotoxicity (liver problems), and certain cardiac rhythm disturbances. This information is typically presented in a prominent manner within the prescribing documents.

Q: What happens if a person misses a single dose of Itraconazol Generis?

A: If a dose is missed, official regulatory guidance advises the patient not to take a double dose to make up for the one that was missed. Guidance on how to proceed with the regimen is typically handled by a healthcare provider.

Q: Is Itraconazol Generis considered safe for older adults (seniors)?

A: Official documents note that caution is exercised when this medicine is considered for older adults (seniors). This is due to limited specific clinical data for this age group and the possibility of reduced drug clearance (how the body eliminates the drug) over time.

Q: Can people with liver conditions use Itraconazol Generis?

A: Regulatory labeling indicates that use in patients who have existing impaired hepatic function (liver conditions) requires careful monitoring during treatment. The need for specialized monitoring relates to how the medicine is processed and eliminated by the liver.

Q: Is Itraconazol Generis known to interact with herbal supplements like St. John's Wort?

A: The medicine has documented contraindications or restrictions regarding co-administration with strong CYP3A4-inducing substances. Regulatory information specifically mentions that herbal products, such as St. John's Wort, may significantly decrease the amount of Itraconazole in the body, potentially impacting its effectiveness.

Q: Does drinking alcohol while using Itraconazol Generis pose a risk?

A: Some official prescribing information for the medicine includes a clear statement about avoiding alcohol consumption while the medicine is being used.

Q: Are there any food items that should be avoided when taking Itraconazol Generis?

A: Regulatory documents do not formally prohibit specific food items when taking Itraconazol Generis. However, the optimal absorption of the capsule formulation is officially dependent on the capsules being taken immediately after a full meal.

Q: How long does the active ingredient of Itraconazol Generis stay in the body?

A: The terminal half-life of the active ingredient, Itraconazole, is the time it takes for half of the drug to be eliminated from the body. Regulatory documents report this to range from 16 to 28 hours after a single dose, which typically increases to a range of 34 to 42 hours with continued, repeated dosing.

Q: Does Itraconazol Generis cause temporary changes in taste?

A: Yes, the prescribing information lists an unpleasant taste as a possible side effect that has been documented in users of the medicine.

Q: Is Itraconazol Generis the same kind of drug as fluconazole or ketoconazole?

A: Itraconazol Generis is classified pharmacologically as a Triazole Antifungal agent. This places it in the broader Azole Antifungal drug class, which includes related medications such as fluconazole and ketoconazole.

Q: What makes Itraconazol Generis effective against certain types of fungus?

A: The medicine is officially defined as a broad-spectrum antifungal agent intended to treat a wide array of fungal illnesses. It is used to clear both superficial and deep-seated systemic fungal infections caused by susceptible pathogens.

Q: Can Itraconazol Generis be used by children?

A: According to regulatory authorities, the safety and effectiveness of Itraconazol Generis have not been established in the pediatric population. Consequently, official data does not establish its use in children.

Q: What is the guidance regarding the use of Itraconazol Generis during pregnancy or breastfeeding?

A: The use of Itraconazol Generis is generally contraindicated (prohibited) during pregnancy. Official guidance notes that women of childbearing potential must follow highly effective contraception methods during therapy and for two months following its completion. Additionally, official guidance states that lactating women must discontinue breastfeeding while taking the medicine.

Q: Is Itraconazol Generis known to cause skin rashes or sensitivity to the sun?

A: Regulatory documents note the potential for certain skin reactions. These include photosensitivity (increased sensitivity to sun exposure) and urticaria (which is commonly described as hives or a rash).

Q: Is Itraconazol Generis safe for people with kidney problems?

A: Official documents note that caution is exercised for people who have renal (kidney) impairment. This is because kidney function can affect the drug’s clearance, potentially leading to altered exposure in the body.

Q: Is it typical for Itraconazol Generis treatment to last several months?

A: Yes, the duration of treatment is often extended for serious systemic infections. Regulatory documents note that therapy may require several months of treatment until clinical and laboratory clearance of the fungal infection is confirmed.

Q: Does the efficacy of Itraconazol Generis vary based on the type of fungal infection?

A: The established standard regimens and treatment durations described in regulatory documents vary according to the classification of the fungal infection. This difference is based on whether the infection is superficial or deep-seated systemic in nature.

Q: Are eye or vision changes a recognized, though uncommon, side effect of Itraconazol Generis?

A: Official prescribing information lists changes in vision as a potential side effect. Specifically, blurred vision and double vision are recognized, though uncommon, side effects that have been reported by users.

Q: Is Itraconazol Generis used to treat yeast infections?

A: Yes, the medicine is officially indicated for the treatment of certain infections caused by yeast. This includes, for instance, oral candidiasis (thrush) and esophageal candidiasis.

Q: Are there different formulations of Itraconazol Generis available globally?

A: Official documents confirm that the active substance, Itraconazole, is formulated exclusively for oral administration and is supplied in multiple high-level preparations. These typically include the traditional Capsule, the Oral Solution (liquid), and sometimes a Tablet form.

Q: Does Itraconazol Generis have a potential for misuse or dependency?

A: Studies have investigated the potential for misuse or dependency related to this medicine. Research evidence indicates that reports regarding addiction potential are low, with only a small number of such cases observed during the studied trials.

Q: If I am taking blood thinners, is Itraconazol Generis a concern?

A: Anticoagulants (medicines often described as blood thinners) are listed in regulatory documents as a class of drugs that interact with Itraconazol Generis. This interaction is due to the risk of increased exposure of the blood thinner.

Q: Does the drug come with a specific boxed warning in regulatory documents?

A: Yes, the official regulatory labeling for this medicine includes a prominent Boxed Warning. This warning highlights the potential risks related to Congestive Heart Failure (CHF) and specific, significant Drug Interactions.

Q: Can Itraconazol Generis be taken with antacids or medicines for heartburn?

A: The use of antacids is officially restricted relative to the capsule dose. Regulatory documents state that antacids or medicines that reduce gastric acid must be administered at least two hours after taking the capsule formulation to prevent a reduction in the medicine's effectiveness.

Q: Is it necessary to have blood tests while on a course of Itraconazol Generis?

A: Official prescribing information indicates that liver function monitoring is generally a consideration for all patients receiving this medicine. This is part of the overall monitoring process related to potential effects on the liver.

Q: Are there situations where a healthcare provider might stop prescribing Itraconazol Generis?

A: Official information describes conditions under which treatment cessation is indicated, such as experiencing certain serious symptoms. These include signs suggestive of congestive heart failure, symptoms of liver dysfunction, or signs of hearing loss or nerve damage (neuropathy).

Q: Why is monitoring sometimes required for people taking Itraconazol Generis long-term?

A: Monitoring is typically required when the medicine is used for long-term therapy. Official documents state that this is due to the associated risks of peripheral neuropathy (nerve damage) and instances of serious hepatotoxicity (liver problems).

How should Itraconazol Generis be stored and disposed of?

How to Store and Dispose of Itraconazol Generis?

This medication must be stored according to the specific instructions provided on the official regulatory label, which defines strict conditions for temperature, light, and humidity.

Requirement Type	Official Instructions
Temperature & Environment	Store capsules at controlled room temperature (e.g., 20 C to 25 C). Keep the medicine protected from moisture and light.
Handling Restrictions	The oral solution must not be refrigerated or frozen, as stated in the prescribing information.
Packaging	Keep the medicine in its original container, and ensure the bottle or blister pack is tightly closed.
Stability Rule	Any unused portion of the oral solution must be discarded 30 days after the bottle is first opened.
Child Safety	It is mandatory to keep this medicine out of the sight and reach of children at all times.
Disposal Protocol	Unused or expired medication must not be disposed of via household trash or wastewater. Return the product to a pharmacist or use an approved medication take-back program.

Itraconazol Generis